Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 6,247 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,247 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the transaction, the chief executive officer now directly owns 307,415 shares of the company’s stock, valued at approximately $8,822,810.50. This represents a 1.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apellis Pharmaceuticals Trading Down 3.1 %

APLS stock opened at $27.69 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.44 billion, a P/E ratio of -13.64 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The business’s 50 day moving average is $31.86 and its 200-day moving average is $33.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same quarter in the prior year, the company earned ($1.17) earnings per share. The business’s revenue was up 78.3% compared to the same quarter last year. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Citigroup reduced their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Robert W. Baird lowered their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Bank of America cut their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, William Blair initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating on the stock. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.65.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Wolverine Asset Management LLC acquired a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $27,000. True Wealth Design LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $56,000. KBC Group NV boosted its position in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).